Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

  title={Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1},
  author={T-C Teh and Nga Nguyen and Donia M. Moujalled and David Segal and Giovanna Pomilio and Sewa Rijal and Anissa Jabbour and Kyle D. Cummins and Kurt Lackovic and Piers A Blombery and Eli R Thompson and Paul G Ekert and Guillaume Lessene and Stefan P. Glaser and David C S Huang and Andrew W Roberts and Mark A. Guthridge and Andrew H Wei},
Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 inhibitors (for example, venetoclax). We show that venetoclax synergizes with cytarabine and idarubicin to increase antileukemic efficacy in a TP53-dependent manner. Although TP53… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-9 of 9 extracted citations


Publications referenced by this paper.
Showing 1-10 of 52 references

Correlative biomarkers of response to venetoclax in combination with chemotherapy or hypomethylating agents in elderly untreated patients with acute myeloid leukemia

  • B Chyla, R Popovic, J Potluri, J Hayslip, X Huang, M Zhu
  • Blood
  • 2016

Safety and ef fi cacy of venetoclax plus low - dose cytarabine in treatment - naive patients aged X 65 years with acute myeloid leukemia

  • A Wei, SA Strickland, GJ Roboz, Hou J-Z, W Fiedler, TL Lin
  • Blood
  • 2016

Similar Papers

Loading similar papers…